Valeant submits NDA to US FDA for oral Relistor to treat OIC in adults with chronic non-cancer pain
Progenics Pharmaceuticals has exclusively licensed development and commercialization rights for its first commercial product, Relistor, to Valeant. Relistor is a peripherally acting mu-opioid receptor antagonist designed to block
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.